Rus Eng
Main / Company's news / GEROPHARM continues to expand its pipeline of antidiabetic drug products

GEROPHARM continues to expand its pipeline of antidiabetic drug products

23 March 2016

GEROPHARM has received a permission to conduct an international multi-center clinical trial of a new oral drug evogliptin for the treatment of type 2 diabetes mellitus (phase III). The drug was licensed to a large pharmaceutical company Dong-A ST Co., Ltd. (South Korea) in 2015.

Evogliptin belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors or the class of gliptins. In clinical practice gliptins have proved to be safe and effective oral drugs reducing the level of glucose in patients with type 2 diabetes. Today gliptins (DPP-4 inhibitors) occupy more than half of the world’s market of oral antidiabetic drugs, the Russian market share is about 2,5 billion rubles. The drugs of 5 companies are now registered in this class in Russia.

The design of the international clinical trial has been planned in accordance with the requirements of international practice, and it includes the following attributes: double blinding with a double- dummy design. 11 Russian centers and 27 centers in South Korea participate in the research. The company plans to introduce evogliptin into the Russian market at the end of 2017.

You are a health care professional?

Go up